Mark Alan Little

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/480098/publications.pdf

Version: 2024-02-01

150	7,093	76196	62479
papers	citations	40	80
		h-index	g-index

158	158	158	6788
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2016, 75, 1583-1594.	0.5	940
2	Genetically Distinct Subsets within ANCA-Associated Vasculitis. New England Journal of Medicine, 2012, 367, 214-223.	13.9	820
3	Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1036-1043.	0.5	344
4	Severity of renal vascular disease predicts mortality in patients undergoing coronary angiography. Kidney International, 2001, 60, 1490-1497.	2.6	294
5	Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood, 2005, 106, 2050-2058.	0.6	246
6	Monogenic causes of chronic kidney disease in adults. Kidney International, 2019, 95, 914-928.	2.6	174
7	Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nature Communications, 2019, 10, 5120.	5.8	160
8	Anti-Proteinase 3 Anti-Neutrophil Cytoplasm Autoantibodies Recapitulate Systemic Vasculitis in Mice with a Humanized Immune System. PLoS ONE, 2012, 7, e28626.	1.1	147
9	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Annals of the Rheumatic Diseases, 2010, 69, 1744-1750.	0.5	139
10	Anti-Neutrophil Cytoplasmic Antibodies Stimulate Release of Neutrophil Microparticles. Journal of the American Society of Nephrology: JASN, 2012, 23, 49-62.	3.0	132
11	A prospective study of complications associated with cuffed, tunnelled haemodialysis cathetersâ€. Nephrology Dialysis Transplantation, 2001, 16, 2194-2200.	0.4	129
12	Genotypeâ€“phenotype correlations in X-linked myotubular myopathy. Neuromuscular Disorders, 2002, 12, 939-946.	0.3	122
13	Myeloid Engraftment in Humanized Mice: Impact of Granulocyte-Colony Stimulating Factor Treatment and Transgenic Mouse Strain. Stem Cells and Development, 2016, 25, 530-541.	1.1	113
14	Severity of primary MPGN, rather than MPGN type, determines renal survival and post-transplantation recurrence risk. Kidney International, 2006, 69, 504-511.	2.6	112
15	Experimental Autoimmune Vasculitis. American Journal of Pathology, 2009, 174, 1212-1220.	1.9	104
16	Urinary Soluble CD163 in Active Renal Vasculitis. Journal of the American Society of Nephrology: JASN, 2016, 27, 2906-2916.	3.0	101
17	Therapeutic Effect of Antiâ€“TNF-Î± Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibodyâ€“Associated Systemic Vasculitis. Journal of the American Society of Nephrology: JASN, 2006, 17, 160-169.	3.0	98
18	NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient. JCI Insight, 2017, 2, .	2.3	95

#	Article	IF	Citations
19	A cross-sectional study of the Birmingham Vasculitis Activity Score version 3 in systemic vasculitis. Rheumatology, 2011, 50, 899-905.	0.9	89
20	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis: A Randomized Controlled Study. Arthritis and Rheumatology, 2019, 71, 952-963.	2.9	82
21	Spatial and Temporal Clustering of Anti-Glomerular Basement Membrane Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1392-1399.	2.2	80
22	2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmunity Reviews, 2020, 19, 102618.	2.5	79
23	Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis. Transplantation, 2009, 87, 591-605.	0.5	75
24	Renal transplantation in systemic vasculitis: when is it safe?. Nephrology Dialysis Transplantation, 2009, 24, 3219-3225.	0.4	74
25	The characterisation and determinants of quality of life in ANCA associated vasculitis. Annals of the Rheumatic Diseases, 2014, 73, 207-211.	0.5	74
26	Access recirculation in temporary hemodialysis catheters as measured by the saline dilution technique. American Journal of Kidney Diseases, 2000, 36, 1135-1139.	2.1	68
27	Recurrence of hemolytic uremic syndrome after live related renal transplantation associated with subsequent de novo disease in the donor. American Journal of Kidney Diseases, 2002, 40, e22.1-e22.4.	2.1	63
28	Churg-Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax, 2008, 63, 883-888.	2.7	58
29	Injurious Falls and Syncope in Older Community-Dwelling Adults Meeting Inclusion Criteria for SPRINT. JAMA Internal Medicine, 2017, 177, 1385.	2.6	54
30	Neutrophils in COVID-19: Not Innocent Bystanders. Frontiers in Immunology, 2022, 13, .	2.2	52
31	The Irish Kidney Gene Project - Prevalence of Family History in Patients with Kidney Disease in Ireland. Nephron, 2015, 130, 293-301.	0.9	51
32	Explaining fatigue in ANCA-associated vasculitis. Rheumatology, 2013, 52, 1680-1685.	0.9	50
33	Single Agent Antihypertensive Therapy and Orthostatic Blood Pressure Behaviour in Older Adults Using Beat-to-Beat Measurements: The Irish Longitudinal Study on Ageing. PLoS ONE, 2016, 11, e0146156.	1.1	50
34	Intravenous Cyclophosphamide and Plasmapheresis in Dialysis-Dependent ANCA-Associated Vasculitis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 219-224.	2.2	49
35	Neutrophils: Need for Standardized Nomenclature. Frontiers in Immunology, 2021, 12, 602963.	2.2	48
36	Outcome in glomerulonephritis due to systemic small vessel vasculitis: effect of functional status and non-vasculitic co-morbidity. Nephrology Dialysis Transplantation, 2004, 19, 356-364.	0.4	47

#	Article	IF	Citations
37	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. Annals of the Rheumatic Diseases, 2011, 70, 80-85.	0.5	47
38	Animal models of antineutrophil cytoplasm antibody-associated vasculitis. Current Opinion in Rheumatology, 2012, 24, 1-7.	2.0	47
39	Intermediate monocytes in ANCA vasculitis: increased surface expression of ANCA autoantigens and IL-1Î² secretion in response to anti-MPO antibodies. Scientific Reports, 2015, 5, 11888.	1.6	45
40	Low Density Granulocytes in ANCA Vasculitis Are Heterogenous and Hypo-Responsive to Anti-Myeloperoxidase Antibodies. Frontiers in Immunology, 2019, 10, 2603.	2.2	44
41	Development and Evaluation of a Composite Risk Score to Predict Kidney Transplant Failure. American Journal of Kidney Diseases, 2011, 57, 744-751.	2.1	43
42	Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Kidney International Reports, 2018, 3, 1039-1049.	0.4	41
43	Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transplant International, 2000, 13, 443-447.	0.8	40
44	A longitudinal study of the repeated use of alteplase as therapy for tunneled hemodialysis catheter dysfunction. American Journal of Kidney Diseases, 2002, 39, 86-91.	2.1	40
45	Comparison of the Predictive Performance of eGFR Formulae for Mortality and Graft Failure in Renal Transplant Recipients. Transplantation, 2009, 87, 384-392.	0.5	40
46	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology Dialysis Transplantation, 2020, 35, 283-291.	0.4	40
47	A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibodyâ€“associated vasculitis. Rheumatology, 2019, 58, 260-268.	0.9	40
48	Technetium Myocardial Perfusion Scanning in Prerenal Transplant Evaluation in the United Kingdom. Transplantation Proceedings, 2008, 40, 1324-1328.	0.3	38
49	Markers for work disability in anti-neutrophil cytoplasmic antibody-associated vasculitis. Rheumatology, 2014, 53, 953-956.	0.9	38
50	International Consensus on Antineutrophil Cytoplasm Antibodies Testing in Eosinophilic Granulomatosis with Polyangiitis. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1360-1372.	2.5	36
51	Identification of the Optimal Donor Quality Scoring System and Measure of Early Renal Function in Kidney Transplantation. Transplantation, 2009, 87, 578-586.	0.5	35
52	Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVIDâ€19: A Binational, Registryâ€Based Cohort Study. Arthritis and Rheumatology, 2021, 73, 1713-1719.	2.9	35
53	Urinary and serum soluble CD25 complements urinary soluble CD163 to detect active renal anti-neutrophil cytoplasmic autoantibody-associated vasculitis: a cohort study. Nephrology Dialysis Transplantation, 2019, 34, 234-242.	0.4	33
54	Environmental risk factors associated with ANCA associated vasculitis: A systematic mapping review. Autoimmunity Reviews, 2020, 19, 102660.	2.5	32

#	Article	IF	Citations
55	The Dutch Transplantation in Vasculitis (DUTRAVAS) Study. Transplantation, 2016, 100, 916-924.	0.5	29
56	Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome. Kidney International Reports, 2018, 3, 784-793.	0.4	28
57	Targeting of the cGAS-STING system by DNA viruses. Biochemical Pharmacology, 2020, 174, 113831.	2.0	28
58	Anti-myeloperoxidase antibodies attenuate the monocyte response to LPS and shape macrophage development. JCI Insight, 2017, 2, e87379.	2.3	28
59	The diagnostic yield of intravenous urography. Nephrology Dialysis Transplantation, 2000, 15, 200-204.	0.4	27
60	The Impact of Hemoglobin Levels on Patient and Graft Survival in Renal Transplant Recipients. Transplantation, 2008, 86, 564-570.	0.5	27
61	Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. BMJ, The, 2022, 376, e064597.	3.0	25
62	Glomerulonephritis due to antineutrophil cytoplasm antibody-associated vasculitis: An update on approaches to management. Nephrology, 2005, 10, 368-376.	0.7	24
63	Induction treatment of ANCA-associated vasculitis with a single dose of rituximab. Rheumatology, 2014, 53, 1395-1403.	0.9	24
64	In vivo approaches to investigate ANCA-associated vasculitis: lessons and limitations. Arthritis Research and Therapy, 2010, 13, 204.	1.6	23
65	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open, 2017, 3, e000449.	1.8	23
66	Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis. Current Opinion in Rheumatology, 2014, 26, 37-41.	2.0	22
67	Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific manifestations of renal injury. Clinical and Experimental Immunology, 2018, 191, 180-188.	1.1	22
68	Hemolytic-uremic syndrome in association with both cyclosporine and tacrolimus. Transplant International, 2000, 13, 443-447.	0.8	22
69	Changes in urinary metabolomic profile during relapsing renal vasculitis. Scientific Reports, 2016, 6, 38074.	1.6	21
70	The European Vasculitis Society 2016 Meeting Report. Kidney International Reports, 2017, 2, 1018-1031.	0.4	21
71	Autosomal dominant tubulointerstitial kidney disease (ADTKD) in Ireland. Renal Failure, 2019, 41, 832-841.	0.8	21
72	MESANGIOPROLIFERATIVE GLOMERULONEPHRITIS WITH IgM DEPOSITION: CLINICAL CHARACTERISTICS AND OUTCOME. Renal Failure, 2000, 22, 445-457.	0.8	20

#	Article	IF	Citations
73	Association of venous thromboembolic events with skin, pulmonary and kidney involvement in ANCA-associated vasculitis: a multinational study. Rheumatology, 2021, 60, 4654-4661.	0.9	20
74	Pregnancy in Irish renal transplant recipients in the cyclosporine era. Irish Journal of Medical Science, 2000, 169, 19-21.	0.8	17
75	Graded Association Between Kidney Function and Impaired Orthostatic Blood Pressure Stabilization in Older Adults. Journal of the American Heart Association, 2017, 6, .	1.6	17
76	Review article: Leukocyteâ€endothelial dysregulation in systemic small vessel vasculitis. Nephrology, 2009, 14, 3-10.	0.7	16
77	Short-Chain Acyl-CoA Dehydrogenase Deficiency Associated with Early Onset Severe Axonal Neuropathy. Neuropediatrics, 2004, 35, 312-316.	0.3	15
78	Effect of Disease Activity at Three and Six Months After Diagnosis on Longâ€Term Outcomes in Antineutrophil Cytoplasmic Antibodyâ€“Associated Vasculitis. Arthritis and Rheumatology, 2019, 71, 784-791.	2.9	15
79	Utility of Genomic Testing after Renal Biopsy. American Journal of Nephrology, 2020, 51, 43-53.	1.4	15
80	The McKittrick-Wheelock Syndrome: A Case of Acute Renal Failure Due to Neoplastic Cholera. Renal Failure, 2008, 30, 469-473.	0.8	14
81	The utility of a genetic kidney disease clinic employing a broad range of genomic testing platforms: experience of the Irish Kidney Gene Project. Journal of Nephrology, 2022, 35, 1655-1665.	0.9	14
82	Kidney Function Estimated From Cystatin C, But Not Creatinine, Is Related to Objective Tests of Physical Performance in Community-Dwelling Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, 1554-1560.	1.7	13
83	Predictors of Renal Outcomes in Sclerotic Class Anti-Neutrophil Cytoplasmic Antibody Glomerulonephritis. American Journal of Nephrology, 2018, 48, 465-471.	1.4	13
84	The complications of vasculitis and its treatment. Best Practice and Research in Clinical Rheumatology, 2018, 32, 125-136.	1.4	13
85	The Clinical Application of Urine Soluble CD163 in ANCA-Associated Vasculitis. Journal of the American Society of Nephrology: JASN, 2021, 32, 2920-2932.	3.0	12
86	A cohort study to investigate sex-specific differences in ANCA-associated glomerulonephritis outcomes. Scientific Reports, 2021, 11, 13080.	1.6	11
87	Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity. Viruses, 2021, 13, 1371.	1.5	11
88	Immune Profile and Epstein-Barr Virus Infection in Acute Interstitial Nephritis: An Immunohistochemical Study in 78 Patients. Nephron Clinical Practice, 2011, 119, c293-c300.	2.3	10
89	Getting the balance right: adverse events of therapy in anti-neutrophil cytoplasm antibody vasculitis. Nephrology Dialysis Transplantation, 2015, 30 Suppl 1, i164-70.	0.4	10
90	Waldenstrom's Macroglobulinemia Presenting as Goodpasture's Syndrome. Renal Failure, 2004, 26, 591-596.	0.8	9

#	Article	IF	Citations
91	Percutaneous venepuncture practice in a large urban teaching hospital. Clinical Medicine, 2007, 7, 243-249.	0.8	9
92	Automated oyster shucking. Aquacultural Engineering, 2007, 37, 35-43.	1.4	9
93	ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype. Kidney International, 2017, 92, 544-546.	2.6	9
94	Rapidly progressive glomerulonephritis: current and evolving treatment strategies. Journal of Nephrology, 2004, 17 Suppl 8, S10-9.	0.9	9
95	FAIRVASC: A semantic web approach to rare disease registry integration. Computers in Biology and Medicine, 2022, 145, 105313.	3.9	9
96	A Longitudinal Study of the Yield and Clinical Utility of a Specifically Designed Secondary Hypertension Investigation Protocol. Renal Failure, 2003, 25, 709-717.	0.8	8
97	Polymyalgia rheumatica preceding small-vessel vasculitis: changed spots or misdiagnosis?. QJM - Monthly Journal of the Association of Physicians, 2004, 97, 289-292.	0.2	8
98	Prolonged Duration of Renal Recovery Following ANCA-Associated Glomerulonephritis. American Journal of Nephrology, 2016, 43, 112-119.	1.4	8
99	The relationship between kidney function and quality of life among community-dwelling adults varies by age and filtration marker. CKJ: Clinical Kidney Journal, 2018, 11, 259-264.	1.4	8
100	Towards European harmonisation of healthcare for patients with rare immune disorders: outcome from the ERN RITA registries survey. Orphanet Journal of Rare Diseases, 2020, 15, 33.	1.2	8
101	ANCA Vasculitis Induction Management During the COVID-19 Pandemic. Kidney International Reports, 2021, 6, 2903-2907.	0.4	8
102	Peritonitis, peritoneal inflammation and membrane permeability: a longitudinal study of dialysate and serum MCP-1 in stable patients on peritoneal dialysis. Journal of Nephrology, 2007, 20, 340-9.	0.9	8
103	Automated oyster shucking. Aquacultural Engineering, 2007, 37, 24-34.	1.4	7
104	Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults. Journal of Epidemiology and Community Health, 2018, 72, 287-293.	2.0	7
105	Kidney Disease in Women is Associated with Disadvantaged Childhood Socioeconomic Position. American Journal of Nephrology, 2018, 47, 292-299.	1.4	7
106	Pro-inflammatory Stimulation of Monocytes by ANCA Is Linked to Changes in Cellular Metabolism. Frontiers in Medicine, 2020, 7, 553.	1.2	7
107	Spinal Cord Infarction Following Central-Line Insertion. Renal Failure, 2003, 25, 327-329.	0.8	6
108	Familial MPGN â€“ a case series: a clinical description of familial membranoproliferative glomerulonephritis amongst three Irish families. Renal Failure, 2014, 36, 1333-1336.	0.8	6

#	Article	IF	Citations
109	The Janus Faces of IL-6 in GN. Journal of the American Society of Nephrology: JASN, 2015, 26, 1480-1482.	3.0	6
110	Investigation of type I interferon responses in ANCA-associated vasculitis. Scientific Reports, 2021, 11, 8272.	1.6	6
111	Fortuitous Vasculitis. Renal Failure, 2012, 34, 378-382.	0.8	5
112	Elevated active secretory sphingomyelinase in antineutrophil cytoplasmic antibody-associated primary systemic vasculitis. Annals of the Rheumatic Diseases, 2012, 71, 1100-1102.	0.5	5
113	Patient Outcomes in Renal-Limited Antineutrophil Cytoplasmic Antibody Vasculitis With Inactive Histology. Kidney International Reports, 2018, 3, 671-676.	0.4	5
114	Pathogenesis of ANCA-associated vasculitis: an emerging role for immunometabolism. Rheumatology, 2020, 59, iii33-iii41.	0.9	5
115	Study protocol for theÂSt James's Hospital, Tallaght University Hospital, Trinity College Dublin Allied Researchers' (STTAR) Bioresource for COVID-19. HRB Open Research, 0, 5, 20.	0.3	5
116	Pauci Immune crescentic glomerulonephritis in a patient with T-cell lymphoma and argyria. BMC Nephrology, 2016, 17, 49.	0.8	4
117	Comment on: A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibodyâ€“associated vasculitis: reply. Rheumatology, 2019, 58, 738-739.	0.9	4
118	A novel 4-dimensional live-cell imaging system to study leukocyte-endothelial dynamics in ANCA-associated vasculitis. Autoimmunity, 2020, 53, 148-155.	1.2	4
119	Sphingosine-1-phosphate receptor modulator FTY720 attenuates experimental myeloperoxidase-ANCA vasculitis in a T cell-dependent manner. Clinical Science, 2020, 134, 1475-1489.	1.8	4
120	Automated oyster shucking. Aquacultural Engineering, 2007, 37, 44-52.	1.4	3
121	L7. Animal models of PR3-ANCA vasculitis: Approaches and controversies. Presse Medicale, 2013, 42, 512-515.	0.8	3
122	Urine sCD163: a window onto glomerular inflammation. Nephrology Dialysis Transplantation, 2016, 31, 1970-1972.	0.4	3
123	Renal amyloidosis complicating multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2017, 21, 476-477.	0.6	3
124	Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney International, 2018, 94, 926-936.	2.6	3
125	Data linkage in medical science using the resource description framework: the AVERT model. HRB Open Research, 2018, 1, 20.	0.3	3
126	Data linkage in medical science using the resource description framework: the AVERT model. HRB Open Research, 0, 1, 20.	0.3	3

#	Article	IF	Citations
127	The Sound of Interconnectivity; The European Vasculitis Society 2022 Report. Kidney International Reports, 2022, 7, 1745-1757.	0.4	3
128	Anti-proteinase 3 antibody binding to neutrophils as demonstrated by confocal microscopy. Kidney International, 2005, 68, 2912-2913.	2.6	2
129	Dialysis amyloid: the bottom line. Nephrology Dialysis Transplantation, 2005, 20, 462-463.	0.4	2
130	334.â€ƒUK & Ireland Vasculitis Registry (Ukivas): Cross-Sectional Data on the First 556 Patients. Rheumatology, 2014, 53, i184-i185.	0.9	2
131	Releasing the complement brakes: is myeloperoxidase the missing link between factor H and C5a in anti-neutrophil cytoplasmic antibody vasculitis?. Rheumatology, 2018, 57, 2070-2071.	0.9	2
132	Renal transplant outcomes in patients with autosomal dominant tubulointerstitial kidney disease. Clinical Transplantation, 2020, 34, e13783.	0.8	2
133	The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset. Arthritis Research and Therapy, 2022, 24, .	1.6	2
134	Response to â€˜Differences between type I and II membranoproliferative glomerulonephritisâ€™. Kidney International, 2006, 70, 1527.	2.6	1
135	The Beneficial Effects of Statin Therapy May Not Apply to All Forms of Crescentic Glomerulonephritis. American Journal of Pathology, 2011, 178, 2447-2448.	1.9	1
136	Comment on: Induction treatment of ANCA-associated vasculitis with a single dose of rituximab: reply. Rheumatology, 2015, 54, 373-374.	0.9	1
137	Acute renal allograft failure in a patient with vasculitis. Rheumatology, 2021, 60, iii43-iii46.	0.9	1
138	Small vessel vasculitides. Medicine, 2010, 38, 84-92.	0.2	0
139	Autoimmune rheumatic diseases: an introduction. Medicine, 2010, 38, 67-68.	0.2	0
140	Fortuitous vasculitis. Journal of Infection, 2011, 63, 504-505.	1.7	0
141	The role of quantitative trait loci (QTL) in the pathogenesis of experimental autoimmune vasculitis (EAV). Presse Medicale, 2013, 42, 688.	0.8	0
142	Induction treatment of ANCA associated vasculitis with a single dose of rituximab. Presse Medicale, 2013, 42, 773.	0.8	0
143	FP161ANCA AND ANTIâ€'GBM DOUBLE POSITIVITY: A CASE SERIES. Nephrology Dialysis Transplantation, 2015, 30, iii120-iii120.	0.4	0
144	185.â€ƒGENETIC EVIDENCE OF EOSINOPHIL NUMBER UNDERPINNING PR3-AAV AND PLAUSIBLE HOST GENETIC PREDISPOSITION TO MICROBIAL DRIVERS OF DISEASE. Rheumatology, 2019, 58, .	0.9	0

#	Article	IF	Citations
145	294.â€ƒRARE IS WHAT MATTERS: CHILDHOOD VASCULITIS IN EU PROJECTS. Rheumatology, 2019, 58, .	0.9	0
146	321.â€ƒLONG-TERM FOLLOW UP OF A GLUCOCORTICOID-MINIMIZING REGIMEN FOR REMISSION-INDUCTION IN ANCA- ASSOCIATED VASCULITIS. Rheumatology, 2019, 58, .	0.9	0
147	Coaxing Anti-Inflammatory Granulocytes to Prevent Ischemic Kidney Injury: A Fine Balance. Journal of the American Society of Nephrology: JASN, 2020, 31, 668-670.	3.0	0
148	Study Protocol for DeCOmPRESS: Defining the Disease Course and Immune Profile of COVID-19 in the Immunosuppressed Patient. HRB Open Research, 0, 4, 6.	0.3	0
149	Intravital microscopy in the study of ANCA-associated systemic vasculitis. Clinical Nephrology, 2005, 64, 465-470.	0.4	0
150	MO214: Health-Related Quality of Life Among Patients With Anca Vasculitis. Nephrology Dialysis Transplantation, 2022, 37, .	0.4	0